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(E)-5-(Pyrimidin-5-yl)-1,2,3,4,7,8-hexahydroazocine (TC299423) is a novel agonist for
nicotinic acetylcholine receptors (nAChRs). We examined its efficacy, affinity, and
potency for α6β2∗ (α6β2-containing), α4β2∗, and α3β4∗ nAChRs, using [125I]-epibatidine
binding, whole-cell patch-clamp recordings, synaptosomal 86Rb+ efflux, [3H]-dopamine
release, and [3H]-acetylcholine release. TC299423 displayed an EC50 of 30–60 nM
for α6β2∗ nAChRs in patch-clamp recordings and [3H]-dopamine release assays. Its
potency for α6β2∗ in these assays was 2.5-fold greater than that for α4β2∗, and
much greater than that for α3β4∗-mediated [3H]-acetylcholine release. We observed no
major off-target binding on 70 diverse molecular targets. TC299423 was bioavailable
after intraperitoneal or oral administration. Locomotor assays, measured with gain-
of-function, mutant α6 (α6L9′S) nAChR mice, show that TC299423 elicits α6β2∗
nAChR-mediated responses at low doses. Conditioned place preference assays show
that low-dose TC299423 also produces significant reward in α6L9′S mice, and modest
reward in WT mice, through a mechanism that probably involves α6(non-α4)β2∗
nAChRs. However, TC299423 did not suppress nicotine self-administration in rats,
indicating that it did not block nicotine reinforcement in the dosage range that was
tested. In a hot-plate test, TC299423 evoked antinociceptive responses in mice similar
to those of nicotine. TC299423 and nicotine similarly inhibited mouse marble burying as
a measure of anxiolytic effects. Taken together, our data suggest that TC299423 will be
a useful small-molecule agonist for future in vitro and in vivo studies of nAChR function
and physiology.
Keywords: nicotine addiction, nicotinic acetylcholine receptors, neuroprotection, electrophysiology, transmitter
release, α6β2∗, hexahydroazocine, pyrimidine
INTRODUCTION
Nicotine is believed to be the primary rewarding and addictive compound in tobacco. It also
improves cognition and attention (Newhouse et al., 2012), and may reduce the lifetime risk of
developing Parkinson’s disease (PD) (Quik and Wonnacott, 2011). These effects are mediated by
binding to nicotinic acetylcholine receptors (nAChRs) in the brain (Picciotto et al., 2008; Srinivasan
et al., 2014; Henderson and Lester, 2015). Neuronal nAChRs are pentameric, ligand-gated, cation-
selective channels formed from α2 – α10 and β2 – β4 subunits. The heteromeric subtypes contain
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α and β subunits in a 2:3 or 3:2 (α:β) stoichiometric ratio (Nelson
et al., 2003). Neuronal nAChRs are present on presynaptic
terminals where they modulate the release of neurotransmitters
such as dopamine (Gotti et al., 2006; Dani and Balfour, 2011).
The subunit composition of the nAChR subtypes determines
their pharmacological and biophysical properties, and partially
governs their anatomical and subcellular distribution (Jensen
et al., 2005).
β2-containing (β2∗) nAChRs are among the most nicotine-
sensitive subtypes in the brain, responding to agonist
concentrations in the 0.2–0.5 µM range (Matta et al., 2007;
Kuryatov and Lindstrom, 2011), and play a crucial role in
nicotine reward and reinforcement (Picciotto et al., 1998; Maskos
et al., 2005; Walters et al., 2006). Mice with β2 genetic deletions
(β2KO) self-administer cocaine (Picciotto et al., 1998), but not
nicotine (Picciotto et al., 1998; Maskos et al., 2005; Pons et al.,
2008), and β2KO mice fail to show conditioned place preference
(CPP) for nicotine (Walters et al., 2006). α4β2∗ nAChRs are the
most common brain subtype, and play a major role in nicotine
reward and reinforcement (Picciotto et al., 1998; Tapper et al.,
2004; Pons et al., 2008; McGranahan et al., 2011); however, their
widespread distribution (Gotti et al., 2006; Baddick and Marks,
2011) means that they may not be the optimal target for smoking
cessation, particularly because their persistent activation may
induce depressive behavior (Janowsky et al., 1972).
The CNS expression of α6β2∗ receptors is more limited than
that of α4β2∗ nAChRs. α6β2∗ nAChRs are selectively expressed in
dopaminergic neurons of the ventral tegmental area (VTA) and
substantia nigra pars compacta (SNc) as well as neurons in the
retina, superior colliculus (Champtiaux et al., 2003; Mackey et al.,
2012; Henderson et al., 2014), medial habenula (Henderson et al.,
2014; Shih et al., 2014), and locus coeruleus. α6∗ nAChRs are
also expressed in the peripheral nervous system where they can
interact with P2X receptors (Limapichat et al., 2014; Wieskopf
et al., 2015). The localization of α6β2∗ nAChRs on dopaminergic
neurons suggests they may play a significant role in nicotine
reward and contribute to nicotine-mediated neuroprotection
against PD (Quik and Wonnacott, 2011). Indeed, selective
activation of hypersensitive α6∗ nAChRs in transgenic mice by
low doses of nicotine is sufficient to establish CPP (Drenan et al.,
2012). Moreover, α6KO mice fail to self-administer nicotine, a
behavior that can be rescued by selectively re-expressing α6∗
nAChRs in the VTA (Pons et al., 2008). Taken together, these
results suggest that α6β2∗ nAChRs are potential targets for
smoking cessation and PD neuroprotection therapeutics.
α-Conotoxin MII (and derivatives) are useful probes for
processes mediated by α6∗ nAChRs (Azam et al., 2010; Perez-
Alvarez et al., 2011; Hone et al., 2012, 2013; McClure-Begley
et al., 2012; Marks et al., 2014). Pioneering studies also identified
a series of drug-like small molecule α6∗ nAChR inhibitors
(Zhang et al., 2011). There are also potential, small-molecule α6∗-
selective agonists that bind to α4β2∗ nAChRs and α6β2∗ nAChRs
(Breining et al., 2009; Marks et al., 2009) or α6β4 nAChRs (Lowe
et al., 2010).
Here, we introduce a novel nAChR agonist, (E)-5-(pyrimidin-
5-yl)-1,2,3,4,7,8-hexahydroazocine (TC299423). We compare
TC299423 to other well-characterized nAChR ligands (nicotine
and varenicline) using in vitro and in vivo assays. The results
show that TC299423 is a potent agonist for β2∗ nAChRs,
and may show a modest preference for α6β2∗ over α4β2∗
nAChRs. Bioavailability assays show that TC299423 enters
the brain. Locomotor assays using transgenic mice expressing
hypersensitive α6∗ nAChRs confirm that TC299423 potently
activates α6∗ nAChRs in vivo. CPP assays using mice with
various nicotinic subunit null mutations further suggest that
TC299423 acts primarily through α6(non-α4)β2∗ nAChRs. Given
that β2∗ nAChRs are implicated in the anxiolytic effects of
nicotine (Turner et al., 2010; Hone et al., 2013), we use a marble-
burying assay to compare the effects of TC299423 to nicotine and
varenicline. We also compare the effects of TC299423 to those
of nicotine and varenicline for their antinociceptive properties.
The results show that TC299423 is a potent nAChR ligand that
may useful in the future study of nAChR function and physiology
using in vivo and in vitro models.
MATERIALS AND METHODS
Mice
C57BL/6 mice (ages 3–6 months) used in this study were
bred and maintained at the California Institute of Technology
(Caltech) or the University of Colorado Boulder. After weaning
at 21 days, same sex littermates were housed no more than 4
(Caltech) or 5 (Colorado) to a cage. Mice of the α4 subunit null
mutant line (Marubio et al., 1999), the α6 subunit null mutant
line (Champtiaux et al., 2002), and the hypersensitive α6L9’S
transgenic mice (Drenan et al., 2008) were bred and maintained
as above and genotyped as previously described (Marubio et al.,
1999; Champtiaux et al., 2003; Drenan and Lester, 2012). Mice
had free access to food and water and were maintained on a
12/12-h light/dark cycle at 22◦C. All experiments were conducted
with the approval of the California Institute of Technology
Animal Care and Use Committee. C57BL/6J strain mice, as well
as α4, α5, and β2 subunit null mutant mice on this background,
were bred and maintained at the Institute for Behavioral Genetics,
University of Colorado Boulder, CO, United States. Animal
care and procedures were approved by the Animal Care and
Utilization Committee of the University of Colorado, Boulder.
Rats
Rat experiments were conducted in adherence with the National
Institutes of Health guidelines and approved by the Institutional
Animal Care and Use Committee of Mt. Sinai, New York,
NY, United States. Male Wistar rats (n = 8; Charles River
Laboratories, Raleigh, NC) weighing 300 g at the start of
experiments were housed in groups of 1–2 per cage in an
environmentally controlled vivarium on a 12 h reverse light-dark
cycle. Prior to the commencement of behavioral testing, all rats
had ad libitum access to food and water.
Compounds and Reagents
TC299423, (E)-5-(pyrimidin-5-yl)-1,2,3,4,7,8-hexahydroazocine,
was synthesized at Targacept. A full report on the synthesis
of TC299423 is in preparation. Varenicline tartrate was also
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synthesized by Targacept. [125I]-Epibatidine (2200 Ci/mmol),
[3H]dopamine (3,4-[ring-2,5,6-3H], 30–60 Ci/mmol),
[3H]choline (methyl-3H, 60–90 Ci/mmol), and carrier-free
86RbCl were purchased from Perkin Elmer Life Sciences, Boston,
MA, United States. α-Conotoxin MII (α-CtxMII) was obtained
from J. Michael McIntosh, University of Utah, Salt Lake City,
UT, United States. The following chemicals as well as all buffer
components (Reagent Grade) were products of Sigma–Aldrich
(St. Louis, MO, United States): (L)-nicotine hydrogen tartrate,
mecamylamine, atropine, bovine serum albumin (BSA), (±)-
epibatidine, HEPES, nomifensine, pargyline, and tetrodotoxin.
All compounds were dissolved in physiological saline (0.9%
NaCl). Concentrations refer to the free base.
Biochemistry and Physiology
Ligand Binding
The methods used for preparing brain membranes in hypotonic
buffer have been described previously (Marks et al., 1998, 2007).
Brain membrane preparations were stored as pellets under buffer
at−70◦C or used immediately. We followed previously published
methods for [125I]epibatidine binding and analysis (Grady et al.,
2010).
Synaptosome Preparation
Regions of interest were dissected from fresh mouse brains and
homogenized in ice-cold isotonic sucrose (0.32 M), buffered
with HEPES (5 mM, pH 7.5). The suspension was centrifuged
at 12,000 × g for 20 min. The pellet was re-suspended in the
appropriate uptake buffer (Grady et al., 2001; Salminen et al.,
2004; Marks et al., 2006) and used immediately.
[3H]Dopamine Uptake and Release
Superfusion was carried out at 22◦C using a buffer containing:
NaCl, 128 mM; KCl, 2.4 mM; CaCl2, 3.2 mM; MgSO4, 1.2 mM;
KH2PO4, 1.2 mM; HEPES, 25 mM; glucose, 10 mM; ascorbic
acid, 1 mM; pargyline, 0.01 mM; 0.1% BSA; nomifensine, 1 µM
(to prevent the re-uptake of dopamine); atropine, 1 µM (to
prevent muscarinic receptor activation); pH 7.5. Superfusion
proceeded at 0.7 mL/min for 10 min before stimulation with
agonist for 20 s. Selected aliquots were perfused with α-CtxMII
(50 nM) for 3 min immediately before stimulation. This
concentration of α-CtxMII was sufficient to inhibit α6β2∗-
nAChRs in the mouse striatum (Salminen et al., 2004, 2007).
Fractions (∼0.1 mL) were collected into 96-well plates at 10 s
intervals for 4 min (starting ∼1 min before stimulation). After
adding 0.15 mL of Optiphase SuperMix scintillation cocktail,
radioactivity was measured using a 1450 MicroBeta TriLux
counter (Perkin Elmer Life Sciences).
Previously published methods for [3H]ACh release from crude
IPN synaptosomes were followed (Grady et al., 2001). Agonist-
stimulated 86Rb+ eﬄux from synaptosomes was measured using
previously described methods (Marks et al., 1999, 2007).
Neuro-2a Cell Culture
Mouse neuroblastoma 2a (neuro-2a) cells, obtained from ATCC
(Cat #: CCL-131, purchased: January 2012), were cultured using
previously described methods (Xiao et al., 2011). The β2DM
subunit bears mutations in the M3–M4 intracellular loop that
enhance exit from the endoplasmic reticulum for both α4β2
and α6β2 nAChRs (Srinivasan et al., 2011; Xiao et al., 2011;
Henderson et al., 2014). Cells were transfected with 500 ng of:
α4-GFP and β2DM or α6-GFP, β2DM, and β3 nAChR subunits.
Plasmids were mixed with 250 µL of Opti-MEM reduced
serum medium (Life Technologies). Lipofectamine 2000 (Life
Technologies) was separately added to 250 µL of Opti-MEM.
After 5 min at 24◦C, DNA and Lipofectamine solutions were
combined and incubated for another 25 min at 24◦C. The
resulting solution was added to pre-plated neuro-2a cells and
incubated for 24 h. After 24 h, the Opti-MEM was removed and
replaced with culture medium.
Patch-Clamp Recordings
For the patch-clamp experiments, we used mouse neuro-2a
cells. 50,000 neuro-2a cells (transfected as described above) were
plated onto sterilized 12 mm glass coverslips (Deckgläser, Prague,
Czechia), placed in 35-mm culture dishes, and cultured in a
humidified incubator (37◦C, 95% air, 5% CO2). Transfected cells
displaying eGFP fluorescence were identified for patching using
an inverted epifluorescence microscope. The pipette solution
contained (in mM): 135 K gluconate, 5 KCl, 5 EGTA, 0.5
CaCl2, 10 HEPES, 2 Mg-ATP, and 0.1 GTP (pH adjusted to
7.2 with Tris-base, osmolarity adjusted to 280–300 mOsm with
sucrose). The resistance of the patch pipettes was 2–4 M.
The extracellular solution contained (in mM): 140 NaCl, 5 KCl,
2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose (320 mOsm,
pH set to 7.3 with Tris-base). The cells were voltage-clamped
in whole-cell mode using an Axopatch 1D amplifier (Axon
Instruments), and the data were recorded with a Digidata
1440A analog-to-digital converter (Axon Instruments) and the
pCLAMP V.10 software (Axon Instruments). The data were
sampled at 10 kHz and low-pass filtered at 2 kHz prior to
digitization. All experiments were performed at 24◦C and the
recording chamber was continually perfused with extracellular
solution. To avoid receptor desensitization by repetitive agonist
application, agonists were applied at intervals ≥3 min. An
Octaflow II superfusion system (ALA Scientific Instruments) was
used to apply the agonist for concentration-response studies.
Applications were 500 ms at 6 psi. For the generation of
concentration response curves, test pulses were applied to assess
functional run-down (three pulses at 0.5 µM TC299423 or
1.0 µM TC299423 for α6-GFPβ2DMβ3 and α4β2DM nAChRs,
respectively). Following the collection of the full concentration
range an additional test pulse was repeated to assess accumulated
desensitization.
Data Analysis for Patch-Clamp Assays
Data were fit to a single Hill term using Origin 10 software.
Data are expressed as mean ± SEM. The SEM values were
calculated from the EC50 values obtained for each individual
concentration-response obtained for α6-GFPβ2β3 or α4-GFPβ2
nAChRs (n=> 5 and 4, respectively). For both α6-GFPβ2β3 and
α4-GFPβ2 nAChRs we used peak current amplitude, normalized
to the response of 1 µM TC299423.
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Behavioral Assays
For the mouse behavioral assays all drugs were dissolved in sterile
0.9% saline and were administered in an injection volume of
0.1 ml/g. Drug doses are expressed as free base.
Locomotor Assays
Mice were habituated to the experimental room for 2 h prior
to the experiment. Horizontal locomotor activity was recorded
using an infrared photobeam activity cage system (San Diego
Instruments; San Diego, CA, United States). After habituating to
the experimental room, mice were placed singly in a novel cage.
Ambulations were recorded when two contiguous photobeams
were broken in succession, preventing activity from being
recorded by most sedentary animals. Ambulation events were
measured for 45 min with four 15 s intervals per min. Mice were
given a total of two intraperitoneal (ip) injections. First, mice
were pre-injected with saline or 1 mg/kg mecamylamine before
being placed in the activity cages. After 8 min in the cage they
were removed, injected with the second drug (saline, nicotine, or
TC299423), and returned again to the cage for the 45 min session.
Conditioned Place Preference
Male, 3–6-month-old mice were used in our CPP assays.
Various genotypes were used: WT, α6L9′S, α4L9′S (hypersensitive
α4∗ and α6∗ nAChRs, respectively), α6KO, α4KO, and β2KO.
All WT mice were C57BL/6J and all other genotypes have
been backcrossed with C57BL/6J mice for ≥10 generations.
The CPP apparatus (Med Associates, East Fairfield, VT,
United States) was a rectangular cage with interior dimensions of
46.5× 12.7× 12.7(H) cm, divided into three sub-compartments:
white and black (each 16.8 cm L) with steel mesh and rod floors,
respectively, and a central gray compartment (7.2 cm L) with
a solid plastic floor. Each compartment had a polycarbonate
hinged lid for loading the animals. Drop-down doors separated
the chambers.
Mice were housed singly and habituated to the experimental
room for 3–7 days before initial testing and remained in the
experimental room for the duration of the experiment. We
chose a biased method for CPP. On day 1 (pre-training) mice
were placed in the center chamber and allowed to explore the
apparatus freely for 20 min. Time spent in each chamber was
recorded, and drug pairing was determined by the least preferred
chamber. Mice with a severe initial bias for one chamber (defined
as≥65% time spent in one conditioning chamber) were excluded.
On days 2, 4, 6, and 8, mice were injected with the drug of interest,
and were confined to the drug-paired chamber for 20 min. On
days 3, 5, 7, and 9, mice were injected with saline and confined
to the opposite chamber. On day 10 (post-training), mice were
again given free access to the apparatus for 20 min, and the time
spent in each chamber was recorded. CPP was determined by
measuring the change in the difference between the time spent
in the drug-paired chamber and the saline-paired chamber from
pre- to post-training.
Marble Burying Assay
Mice were habituated to the experimental room for≥2 h prior to
testing. Fifteen marbles were placed approximately 5 cm apart in
a 5 × 3 marble grid in an activity cage, with 5 cm-deep bedding.
Mice were given ip injections of saline, nicotine, varenicline,
or TC299423 and placed in the cage with the marbles. After
10 min, the mice were returned to their home cages. Marbles were
counted as buried if they were at least 75% covered with bedding.
Each mouse was tested under each experimental condition using
a Latin-square crossover design. A day without testing occurred
between each test.
Hot Plate Assay
Mice were again habituated to the experimental room for
≥2 h prior to testing. Mice were given ip injections of saline,
nicotine, varenicline, or TC299423, 5 min before being placed
on the hot plate apparatus (Harvard Apparatus, Holliston, MA,
United States). This apparatus is a heated metal plate, maintained
at 55◦C, enclosed by a clear acrylic plastic cylinder (∼10 cm
in diameter), within which the mouse is free to move. When
a mouse exhibits evidence of discomfort (such as paw shaking,
paw licking, jumping, or vocalization) or when a cut-off time
of 60 s is reached, it is removed from the apparatus. If the
mouse urinates during the assay, it is immediately removed from
the hot plate. The time that the mouse remains on the hot
plate prior to showing signs of discomfort is recorded. Doses
were administered using a Latin-square crossover design. A day
without testing occurred between each test.
Rat Intravenous Self-Administration
Operant chambers (Med Associates, East Fairfield, VT,
United States) were used for food delivery and the intravenous
self-administration (IVSA) of nicotine. The chambers were
equipped with two response levers (usually designated active and
inactive) with a cue light located above each lever, a food pellet
dispenser located between the levers, and a computer-controlled
injection pump for the scheduled delivery of nicotine via an IV
implanted catheter.
For IV catheter implantation, the rats were anesthetized using
1–3% isoflurane inhalation in oxygen and surgically prepared
with catheters in the left jugular vein (Kenny et al., 2008). The
catheter was passed subcutaneously to a polyethylene assembly
mounted on the animals’ back. Prior to training, rats were food-
restricted so that their body weight was approximately ∼85%
that of free-feeding rats. They were then trained to press an
active lever for 45 mg food pellets on a fixed ratio 5 time-out
20 s (FR5TO20) schedule of reinforcement. An inactive lever was
also present in the operant box. Pressing this lever was recorded
but was not associated with scheduled consequence. Rats were
permitted to respond for food rewards until a reliable response
was achieved, defined as >90 pellets earned per 1 h session for
three consecutive sessions. Rats were then permitted to respond
for food (n = 8) or for nicotine infusions (n = 9) during 1 h
daily sessions under the FR5TO20 schedule. Each food reward
(45 mg pellet) or nicotine reward of 0.19 µmol/kg (0.03 mg/kg)
per infusion over 1 s initiated a 20 s time-out period, signaled
by a light cue located above the active lever, during which time
pressing the active lever was without consequence.
Rats received ip injections of TC299423 (injection volume of
1 mL per 300 g weight). Twenty min after injection, rats were
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placed in the operant boxes and responding for food rewards
or nicotine infusions was recorded. After each session, catheters
were flushed with heparinized saline (30 U per mL) and checked
for leaks or blockages. The effects of vehicle, or TC299423
doses of 0.01–0.08 mg/kg, on food or nicotine responding were
assessed using a within-subjects Latin-square design. Each rat was
permitted to respond for food or nicotine for at least two IVSA
sessions between each TC299423 treatment to allow responding
to return to baseline levels.
Off-Target Binding and Pharmacokinetic
Data
Pharmacological Profiling
NovaScreen assays at PerkinElmer – Caliper Life Sciences
(Waltham, MA, United States) were used to evaluate the affinity
of TC299423 on 70 diverse molecular targets in vitro using
competition radioligand binding assays (see Supplementary
Table S3).
Pharmacokinetics
Pharmacokinetic experiments with TC299423 were performed
by Absorption Systems LP (Exton, PA, United States). Eighteen
male and female mice (20–40 g) were administered TC299423
at an ip dose of 0.3 mg/kg. Blood samples were taken and the
brains were harvested 5 min, 15 min, 30 min, 1 h, 3 h, and 6 h
after drug administration. Fifteen male and female mice (20–
40 g) were administered TC299423 at a dose of 1 mg/kg orally.
Blood and brain samples were obtained at the same time points
as above. Untreated plasma and blood samples were collected
from three mice in the same cohort as the study animals for pre-
dose (time 0) samples. Blood samples were collected by cardiac
puncture and stored in tubes containing sodium heparin before
being processed. Plasma was prepared and frozen for analysis.
Brains were harvested, rinsed, patted dry, weighed, and frozen.
The concentration of TC299423 in brain and plasma samples
was measured using a generic LC-MS/MS method with a
minimum 6-point calibration curve. Matched matrix was used
for preparation of calibration standards. Dosing solutions were
normalized in matched matrix and analyzed in triplicate in the
same analytical batch as the incurred samples.
Radioligand Displacement
Unbound TC299423 concentrations in the brain and blood
of C57BL/6 mice were also measured using a radioligand
displacement assay (Hussmann and Kellar, 2012). Mice were
administered 0.2 mg/kg (free base) TC299423 ip, and euthanized
5, 10, or 20 min after drug injection. Uninjected mice served
as controls (n = 3 for each group). Trunk blood was collected
into heparinized 1.5 mL polyethylene tubes. The tubes were
centrifuged and the serum was collected. Some hemolysis
occurred. The cerebral cortex was dissected, placed in 1 mL of
cold water, homogenized, and diluted to 3 mL with cold water.
Epibatidine saturation curves were constructed for the cortical
samples using eight concentrations of [125I]epibatidine measured
in triplicate (6, 12, 25, 50, 100, 200, 400, and 800 pM). The
final assay volume was 500, and 50 µL of homogenate was
added to each sample. Blanks included 100 µM nicotine. Samples
were incubated at room temperature overnight. The samples
were filtered, washed and counted. Inhibition of [125I]epibatidine
(325 pM) binding was measured by adding 1, 2, 5, 10, or 20 µL of
serum to samples. The washed, particulate fraction from C57BL/6
cortex was the source of the binding sites.
RESULTS
Identification of TC299423
In preparation for the present study, a small-molecule discovery
program using a library of ∼7000 compounds of modest
drugability was conducted at Targacept. Initial screenings of the
library were conducted with few-concentration assays of Ca2+
flux and nAChR binding in transfected cell lines. Molecules with
potential nanomolar to micromolar affinity for α6β2∗ nAChRs
were sought. TC299423 (Figure 1), one of these compounds, was
identified after our previous structure-activity relationship (SAR)
studies on other nAChR subtypes (Breining et al., 2012; Zhang
et al., 2012; Strachan et al., 2014) and on α6β2∗ nAChRs (Breining
et al., 2009; Grady et al., 2010; Strachan et al., 2014). TC299423
was also analyzed in computational studies on homology models
of α6β2 binding sites analogous to those described previously
(Strachan et al., 2014). Assays that assessed metabolism were
also conducted (discussed below, see Supplementary Table S2).
These initial experiments motivated the more detailed studies
in the present paper, and in recently reported structure-function
experiments (Post et al., 2015; Post et al., 2017).
TC299423 can be considered an acrylic metanicotine analog
(1 or 20a, Figure 1). In TC299423, the pyridine ring of
nicotine was replaced by a pyrimidine ring, a substitution
previously shown to increase α6∗ selectivity (Breining et al.,
2009). We also incorporated the N-methyl moiety of the
metanicotine into an additional, 8-membered ring (a 1,2,3,4,7,8-
hexahydroazocine) in an effort to test a hypothesis that
conformational constraints imposed by a cyclic structure would
confer additional selectivity by reducing the conformational
flexibility of the linear metanicotine structure.
Data obtained with an oocyte expression system showed
that TC299423 exhibits a binding mode similar to that of
nicotine at α6β2 nAChRs, forming a relatively weak cation-pi
interaction with a conserved tryptophan residue termed TrpB
(Post et al., 2015). At α4β2 nAChRs, this cation-pi interaction
also occurs. At α4β2 nAChRs, TC299423, like several other
secondary ammonium agonists, makes an additional cation-pi
interaction with a conserved tyrosine termed TyrC2 (Post et al.,
2017).
Pharmacokinetics
The bioavailability of TC299423 was studied by measuring
its plasma and brain concentration in mice after ip or oral
administration (Figure 2). TC299423 reached a maximum
plasma concentration of 49 ± 18 ng/ml (0.26 µM) 0.08 h after
a 0.3 mg/kg ip injection and had a half-life of 0.17 h in the plasma
(Figure 2A). It reached a maximum brain-tissue concentration
of 22 ± 0.43 ng/g (0.12 µM) 0.5 h after ip injection (Figure 2B).
Oral administration at 1 mg/kg resulted in a maximum plasma
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FIGURE 1 | Relevant chemical structures. Structures for TC299423 (189 g/mol), (+)-PHT (molecular mass, 188 g/mol) which has also been tested as a potential α6∗
selective compound [62], nicotine (162 g/mol), 2-(pyridine-3-yl)quinuclidine (188 g/mol), a previous potential lead molecule from a series of metanicotine analogs
(Breining et al., 2009; Grady et al., 2010), and metanicotine (162 g/mol).
FIGURE 2 | Pharmacokinetic measurements for TC299423.
(A) Concentrations of TC299423 in plasma (ng/mL) following ip (0.3 mg/kg)
and oral (1 mg/kg) administration. (B) Concentrations of TC299423 in the
brain (ng/g) following ip (0.3 mg/kg) and oral (1 mg/kg) administration. All data
are mean ± SEM. n = 3 mice. See text for conversion of ng/ml to µM.
concentration of 38 ± 10 ng/ml (0.20 µM) after 0.25 h with a
half-life of 1.12 h in the plasma (Figure 2A). A maximum brain-
tissue concentration of 42 ± 17 ng/g (0.22 µM) was attained at
0.25 h (Figure 2B). Thus, TC299423 enters the plasma, and passes
into the brain, before being completely metabolized. We used a
previously described radioligand displacement assay (Hussmann
and Kellar, 2012) to obtain additional measurements of the
TC299423 concentration in brain tissue ex vivo (Supplementary
Table S1). Similar to the previous pharmacokinetic assay, these
data confirm the penetration of TC299423 into the brain and its
availability to nAChRs, for ≥20 min.
Some aspects of the microsomal metabolism of TC299423,
in comparison to varenicline, were studied in preliminary
experiments. In both human and rat microsomes, TC299423
exhibited a ∼7-fold longer half-life compared to varenicline
(Supplementary Table S2). Using recombinantly expressed
cytochrome P450 enzyme preparations, we also observed that
TC299423 exhibits a more diverse degradation pathway than
varenicline as it is metabolized by more isoforms of cytochrome
P450 enzyme (Supplementary Table S2). These data suggest that
several metabolic pathways contribute to TC299423 degradation.
Thus, it is a candidate for more detailed human metabolism
studies.
Potency and Efficacy of TC299423
We used a variety of assays (whole-cell patch clamp,
synaptosomal [3H]-dopamine release, synaptosomal [3H]-
ACh release, [125I]-epibatidine binding, and 86Rb+ eﬄux)
to measure TC299423 concentration-response relations for
α4β2∗, α6β2∗, and α3β4∗ nAChRs. Figure 3, Tables 1–3, and
Supplementary Figure S1, summarize the data and show that
TC299423 potently activates α6β2∗ nAChRs. The TC299423
concentration-response relations for α4β2 and α6β2β3 nAChRs
were measured by transiently transfecting fluorescently tagged,
mutant α4-GFPβ2DM or α6-GFPβ2DMβ3 nAChRs in neuro-
2a cells, voltage clamping the cells (whole-cell mode), and
applying TC299423 by rapid microperfusion (see Materials and
Methods, Figure 3A). GFP-labeled nAChR subunits were used
to facilitate the identification of neuro-2a cells expressing the
transfected nAChRs and the DM mutation was used to increase
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FIGURE 3 | Concentration-response curves for functional responses of
TC299423 on nAChRs. (A) Concentration-response relations of TC299423 on
α4-GFPβ2DM nAChRs (n = 5–13 cells) and α6-GFPβ2DMβ3 nAChRs (n = 4
cells). (B) Measurement of α4β2∗-mediated α-CtxMII-resistant [3H]-dopamine
release and α6β2∗-mediated (α-CtxMII-sensitive) [3H]-dopamine release from
WT mouse striatal synaptosomes (see Materials and Methods). EC50 values
for (A,B) are given in Table 1. Data for [3H]-dopamine release were
normalized to the maximum response calculated from the non-linear curve fits
of the results to the Michaelis–Menten equation. Maximal response for the
α-CtxMII-resistant release was calculated to be 6.06 ± 0.37 units and
maximal response for the α-CtxMII-sensitive release was 0.93 ± 0.08 units.
For comparison, 10 µM nicotine elicited 7.78 ± 0.83 units for
α-CtxMII-resistant release and 3.63 ± 0.81 units for α-CtxMII-sensitive
release. Data are mean ± SEM. SEM values for the normalized data were
calculated using Taylor’s expansion. Additional data are presented in the
Supplementary Figure S1. (C,D) Representative waveforms of voltage-clamp
currents for TC299423 applications at given concentrations on
α6-GFPβ2DMβ3 and α4-GFPβ2DM nAChRs. Waveforms are from a single cell
for each nAChR subtype. Arrows indicate 500 ms applications and the dotted
red line represents the baseline for measurements.
the surface receptor density (Henderson et al., 2014). EC50 values
were determined by fitting the concentration-response data
to the Hill equation. The EC50 of TC299423 on α4-GFPβ2DM
nAChRs was 0.1 ± 0.02 µM and on α6-GFPβ2DMβ3 nAChRs
was 0.04 ± 0.01 µM (Figure 3A and Table 1). The EC50 for
the α6-GFPβ2DMβ3 nAChRs was significantly less than that
for α4-GFPβ2DM nAChRs (p < 0.05, two-tailed t-test). Thus
TC299423 activated α6-GFPβ2DMβ3 nAChRs significantly more
potently than α4-GFPβ2DM nAChRs.
To compare the efficacy and potency of TC299423 for
native α4β2∗ and α6β2∗ nAChRs, we measured TC299423-
induced [3H]dopamine release from striatal synaptosomes
(Figure 3B and Table 1). Two classes of nAChR subtypes
are responsible for nicotine-induced [3H]dopamine release
from striatal synaptosomes: α-conotoxin MII (α-CtxMII)-
sensitive and α-CtxMII-insensitive nAChRs. These classes are
composed of α6β2∗ and α4(non-α6)β2∗ nAChRs, respectively.
Accordingly, we measured concentration-response relations
for the α-CtxMII-sensitive, and -insensitive, TC299423-
induced [3H]dopamine release. As above, the EC50 values
were obtained from fits to the Hill equation. The EC50 of
TC299423 for α-CtxMII-insensitive [3H]dopamine release was
0.13 ± 0.03 µM and that for α-CtxMII-sensitive release was
0.03 ± 0.01 µM (Figure 3B and Table 1). Thus, consistent
with the patch-clamp data above, the TC299423–induced
[3H]dopamine release assay also suggests that it activates α6β2∗
nAChRs more potently than α4β2∗ nAChRs. Both data sets
suggest that TC299423 activates α6β2∗ nAChRs ∼3-fold more
potently than α4β2∗ nAChRs. We also studied the effects of
TC299423 on [3H]dopamine release using striatal synaptosomes
from α5-KO mice. Genetic deletion of the α5 subunit did
not significantly affect the potency of TC299423-induced
α-CtxMII-sensitive, or -insensitive, [3H]dopamine release
(Table 1).
To study the potency of TC299423 for native α3β4∗ nAChRs,
we prepared synaptosomes from the mouse interpeduncular
nucleus, a region with dense α3β4 nAChR expression (Shih
et al., 2014), and measured TC299423-induced [3H]ACh
release. The EC50 for TC299423-induced [3H]ACh release
was 8.0 ± 0.4 µM (Table 1). Thus, TC299423 was much
less potent at eliciting [3H]ACh release from interpeduncular
nucleus synaptosomes than it was at eliciting [3H]dopamine
release from striatal synaptosomes, suggesting that the drug
activates α6β2∗ and α4β2∗ nAChRs more potently than α3β4∗
nAChRs.
The α4 and β2 nAChR subunits can form functional
nAChRs with different subunit stoichiometries [α4(3)β2(2),
α4(2)β2(3)] and agonist sensitivities (low-, high-sensitivity,
respectively). Receptors with the α4(3)β2(2) stoichiometry are
much less ACh-sensitive than those with the α4(2)β2(3)
stoichiometry (Nelson et al., 2003; Kuryatov et al., 2005).
To compare the efficacy and potency of TC299423 for these
two receptor stoichiometries, we measured TC299423-elicited
86Rb+ eﬄux from mouse thalamic and cortical synaptosomes
(Table 2). The α4(non-α6)β2∗ nAChRs mediate nicotinic
agonist-induced 86Rb+ eﬄux from these synaptosomes (Marks
et al., 2009). The nicotinic antagonist dihydro-β-erythroidine
(DhβE) blocks high-sensitivity α4β2∗ nAChRs more potently
than low-sensitivity α4β2∗ nAChRs (Marks et al., 1999)
and can be used to distinguish between the two receptor
stoichiometries. TC299423 had an EC50 of 0.6–2.0 µM for the
DhβE-sensitive α4β2∗ nAChRs and ≥14 µM for the DhβE-
insensitive α4β2∗ nAChRs (Table 2). Thus, TC299423 more
potently activates high-sensitivity α4(2)β2(3), than low-sensitivity
α4(3)β2(2), nAChRs.
Regarding efficacy, previous data with an oocyte expression
system showed that TC299423 is a partial agonist at α6β2
nAChRs, with an efficacy 59% that of ACh itself (Post et al., 2015).
In the present experiments on neurotransmitter release, we found
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TABLE 1 | EC50 values and Efficacy of TC299423 on nAChRs.
Assay Transfected nAChR Subunits in Neuro-2a Cells
α6β2β3 α4β2 Single
component
Patch clamp
EC50 (µM) 0.04± 0.01 0.10 ± 0.02
Probable nAChR subunit composition in mouse brain
Neurotransmitter
release
α6β2∗a α4β2∗ a Single
component
α3β4∗b α6β2∗a
(α5KO)
α4β2a
(α5KO)
% Efficacy
EC50 (µM)
50± 20%
0.03± 0.01
76 ± 5%
0.13 ± 0.03
100± 16%
8.0 ± 0.4
54 ± 14%
0.05± 0.03
112 ± 9%
0.6 ± 0.1
aData collected from [3H]DA release, striatum. b[3H]ACh release, interpeduncular nucleus TC299423 EC50 and efficacy on nAChRs transfected into neuro-2a cells or
with endogenous α4β2∗, α6β2∗, and α3β4∗-nAChRs in mouse brain tissue. Efficacy values are given as a percent of the response to nicotine, 10 µM. EC50 data are
expressed as mean ± SEM. See Figure 3 and Supplementary Figure S1 for full concentration-response curves.
additional evidence that TC299423 is a partial agonist at α6β2∗
receptors: the maximal release by TC299423 was 50–54% that of
nicotine (Table 1).
We find that TC299423 is roughly as efficacious as nicotine
for high-sensitivity α4β2∗ nAChRs, but a partial agonist on low-
sensitivity α4β2∗ nAChRs (Tables 1, 2). Interestingly, it also
appears to be at least as efficacious as nicotine for α4β2∗ nAChRs
lacking the α5 nAChR subunit (Figure 1, Tables 1, 2, and
Supplementary Table S1). We also find that TC299423 is roughly
as efficacious as nicotine for α3β4∗ nAChRs.
Binding Affinity of TC299423
To determine whether TC299423 displays a higher affinity for
β2∗, than β4∗, nAChRs, we measured its ability to displace
[125I]epibatidine binding to membranes from three brain
regions (see Materials and Methods). [125I]Epibatidine binds
predominantly to the α4β2∗ subtype in cortical membranes,
α3β4∗ in IPN membranes from β2KO mice, and α6β2∗ in
striatal membranes from α4KO mice (Grady et al., 2010). Thus,
the set of K i values for TC299423 to displace [125I]epibatidine
binding in these three regions provides a way to measure
the apparent affinity of these three subtypes. Based on these
measurements, the K i values for the α4β2∗, α6β2∗, and α3β4∗
subtypes were 0.24 ± 0.04, 1.4 ± 0.6, and 18.0 ± 0.7 nM,
respectively (Table 3). Thus, TC299423 binds with higher
affinity to α4β2∗ and α6β2∗, than α3β4∗ nAChRs. K i values
primarily reflect agonist binding to the high-affinity, desensitized
state, whereas EC50 values for functional assays reflect agonist
binding to the free-receptor state. The relationship between
the K i for [125I]epibatidine displacement (Table 3) and the
EC50 for [3H]dopamine release (Table 1) for the α4β2∗ and
α6β2∗ nAChRs is consistent with previous results showing
that α6∗ nAChRs display a ∼10-fold lower K i than EC50,
whereas α4∗ nAChRs display a ∼100-fold difference. Here,
we observed a ∼20-fold difference for α6β2∗ nAChRs and
a ∼500-fold difference for α4β2 nAChRs. This comparison
suggests that agonist-induced, steady-state desensitization is less
pronounced for α6β2∗, than α4β2∗, nAChRs (Grady et al.,
2012).
TC299423 Activity on Non-nAChR
Targets
TC299423 was assessed for binding to 70 different receptors and
other targets at a concentration of 1 µM (Supplementary Table
S3). Assays included the nicotinic drug [3H]epibatidine binding
to α-bungarotoxin-insensitive nAChRs, the 5-HT3 inhibitor
[N-methyl-3H]GR65630 to mouse receptors in N1E-115 cells,
and human receptors expressed in a clonal cell line. Other
assays included monoamine oxidase A, monoamine oxidase B,
5-HT transporter, norepinephrine transporter, and dopamine
transporter, as well as other. G-protein-coupled receptors, ion
TABLE 2 | Efficacy and Potency of TC299423 on stoichiometries of α4β2 nAChRs.
α4β2∗ Two components α4β2 (α5KO)
High-sensitivity
α4(2)β2(3)
Low-sensitivity
α4(3)β2(2)
86Rb+ efflux,
Thalamus
Efficacy 139 ± 14% 32 ± 10% 166 ± 32%
EC50 (µM) 0.6 ± 0.1 10 ± 10 1.6 ± 0.5
86Rb+ efflux,
Cortex
Efficacy 94 ± 7% 39 ± 4% 169 ± 20%
EC50 (µM) 2 ± 2 26 ± 21 2.4 ± 0.7
Efficacy values are given as a percent of the response to nicotine, 10 µM. EC50
data are expressed as mean ± SEM. See Supplementary Figure S1 for full
concentration-response curves.
TABLE 3 | Binding K i of TC299423 on nAChRs.
α4β2∗ Single
component
α6β2∗
(α4KO)
α3β4∗
(β2KO)
[125I]epibatidine
binding
Ki (nM) 0.24 ± 0.04 1.4 ± 0.6 18 ± 0.7
Data are expressed as mean ± SEM.
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channels, enzymes, and transporters. The results showed that,
consistent with the results reported here, TC299423 bound to
neuronal nAChRs (measured by [3H]epibatidine displacement).
It also bound to ATP-sensitive potassium channels, but with
a much lower affinity than to nAChRs. Only these two sites
showed significant binding. Thus, off-target effects are unlikely
to confound our experimental data at TC299423 concentrations
≤1 µM.
TC299423 and Reward-Related Behavior
Previous data show that mutant mice expressing hypersensitive
α6L9′S∗ nAChRs are more sensitive to nicotine-induced CPP
than WT mice, suggesting that α6∗ nAChR activation on its own
can induce CPP (Drenan et al., 2012). Our functional data show
that TC299423 exhibits a modest preference for activating α6∗
nAChRs. Thus, CPP was used to test whether the activation of α6∗
nAChRs by TC299423 is rewarding in mice (Figure 4). We tested
the ability of TC299423 to establish CPP in both WT, and mutant
α6L9′S, mice. Mice were injected with zero (saline-injected), 1,
4, 12, or 25 µg/kg TC299423 during CPP training (see Materials
and Methods). TC299423 had a highly significant overall effect
on the CPP difference score in the mutant α6L9′S mice [One-
way ANOVA, F(4,45) = 6.706, p = 0.0003], but not in WT mice
[One-way ANOVA, F(4,60) = 1.442, p = 0.2312] (Figures 4A,B).
Post hoc comparisons (Tukey HSD) showed that the scores of
α6L9′S mutant mice injected with 1 and 25µg/kg TC299423 were
significantly greater than the saline-injected controls (p < 0.05,
Figure 4B). The ability of low doses of TC299423 to elicit CPP
in the α6L9′S mice suggests that it is rewarding for these mice.
Interestingly, the CPP difference scores for the saline-injected
WT and mutant controls also suggest that WT mice habituate
to the stress of repeated confinement in the least preferred
chamber (i.e., their CPP difference scores are positive), while
α6L9′S mutant mice become sensitized to it (i.e., their CPP
difference scores are negative). For the WT mice, the CPP dose-
response data were fitted to the Michaelis–Menten equation (see
Materials and Methods) with an ED50 value of 4 ± 3 ng/kg,
whereas the lowest dose tested for the α6L9′S mice elicited a
near maximal response, consistent with an ED50 value< 1 ng/kg
(Figures 4A,B). This confirms that mice with hypersensitive
α6L9′S∗ nAChRs were more sensitive to TC299423-induced CPP
than WT mice. Thus, low doses of TC299423 are more rewarding
for the hypersensitive α6L9’S mutant mice than the WT.
Even though TC299423 had no significant overall effect on
CPP in the WT mice (one-way ANOVA, Tukey HSD, p= 0.23), a
t-test revealed a marginally significant increase in CPP difference
score for the 0.012 mg/kg TC299423-injected group, compared
to the saline-injected control (p = 0.047) (Figure 4A). Using
this dose, we examined the importance of individual nAChR
subunits on TC299423 reward-related behavior. We compared
WT mice to α6KO, α4KO, and β2KO mice, all injected with
0.012 mg/kg TC299423. Here, we observed a significant overall
different response to TC299423 among the genotypes [one-
way ANOVA, F(3,47) = 4.825, p = 0.005] (Figure 4C). Genetic
deletion of the α6 and β2 subunits dramatically reduced the CPP
difference scores (p < 0.05), whereas deletion of the α4 subunit
had no effect on the difference scores (Figure 4C). These data
FIGURE 4 | Conditioned place preference (CPP) by genotype and dose.
(A) WT mice were trained with TC299423 using a range of doses (0, 1, 4, 12,
and 25 µg/kg) in a CPP assay (n = 8–23). A Michaelis–Menten curve was
fitted to the data. The ED50 was 4 ± 3 µg/kg. (B) α6L9′S mice were trained in
a CPP assay using the same doses as in (A) (n = 8–10). A Michaelis–Menten
curve is drawn on the data with an ED50 of 0.3 ng/kg to guide the eye; but the
data would be equally well described by any ED50 < 1 ng/kg. (C) Mice of
various genotypes were trained with TC299423 (12 µg/kg) in a CPP assay
(n = 9–23 mice). For all panels, data shown are mean ± SEM: ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001 (one-way ANOVA with post hoc Tukey).
suggest that (1) a low dose of TC299423 (0.012 mg/kg) is weakly
rewarding for WT mice, and (2) this rewarding effect is mediated
by the activation of α6(non-α4)β2∗ nAChRs.
Food Rewards or Nicotine IVSA
The CPP data above suggest that low doses of TC299423
are weakly rewarding for WT mice but do not provide any
information about the potential effects of TC299423 on the
motivational properties of other substances, such as food and
nicotine. Previous results show that nAChR partial agonists such
as varenicline and (+)-PHT (Figure 1) block nicotine-induced
IVSA and CPP (Rollema et al., 2007; Carroll et al., 2015). Thus,
we tested the effects of TC299423 on male Wistar rats trained
to press a lever for food pellets or intravenous nicotine infusions
(Figure 5).
Rats were trained using 45 mg food pellets on a FR5TO20
schedule. Rats were then permitted to respond for food (n = 8)
or nicotine infusions (0.03 mg/kg/inf) (n = 9) during 1 h daily
sessions under the FR5TO20 schedule. TC299423 or vehicle
was administered (ip, 1 mL/300 g weight, doses indicated in
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FIGURE 5 | TC299423 does not alter nicotine IVSA. Pre-injection of TC299423 in rats at doses of 0.01, 0.025, 0.05, or 0.08 mg/kg did not affect food intake (A) or
nicotine IVSA (B) compared to vehicle control (saline). (A1) Dose-response relation for earned food rewards (n = 8) (ns, p = 0.9967). (A2) Dose-response relation for
active lever presses during food responding (ns, p = 0.7861). (B1) Dose-response relation for earned nicotine infusions (0.03 mg/kg) (n = 9) (ns, p = 0.6331). (B2)
Dose-response relation for active lever presses during nicotine self-administration (ns, p = 0.5798). Data presented are mean ± SEM and analyzed using one-way
repeated measures ANOVA.
Figure 5) 20 min before placement in operant boxes. Compared
to vehicle, rats pre-injected with doses of 0.01, 0.025, 0.05, or
0.08 mg/kg TC299423 showed no statistically significant changes
in responding for food pellets or nicotine infusions [one-way
ANOVA: Nicotine (p = 0.6331), Food (p = 0.9967)]. In neither
case did TC299423 change the number of active lever presses.
Thus, low-dose TC299423 did not inhibit the rewarding effects
of food or nicotine.
TC299423 Effect on Locomotion
Locomotor responses to novel stimuli are an index of animal
exploration and anxiety that can also provide a predictive factor
for responses to rewarding drugs (Antoniou et al., 2008). Mice
that exhibit greater motor activity (high responders) in a novel
environment are more likely to be susceptible to rewarding
properties of drugs, compared to mice that exhibit low activity
(low responders). Thus, we used a locomotor assay to compare
the in vivo effects of low doses of TC299423 and nicotine on
WT and α6L9′S mice (see Materials and Methods, Figure 6A).
Mice were injected ip with saline, nicotine (0.08 mg/kg), or
TC299423 (0.09 mg/kg) and their ambulatory activity in a novel
environment was recorded (Figure 6A). (Doses of 0.08 mg/kg
nicotine and 0.09 mg/kg TC299423 are equimolar, 0.5 µmol/kg).
To determine whether the effects of nicotine and TC299423 on
ambulation were driven by nAChR activation, the mice were
also pre-injected with either saline or mecamylamine (1 mg/kg)
(Figure 6A). Both genotype and drug treatment significantly
affected ambulation [two-way ANOVA: genotype, F(1,72)= 15.98,
p < 0.005; drug effect, F(5,72) = 7.70, p < 0.005]. Nicotine and
TC299423 at these doses dramatically increased the ambulatory
activity of the mutant α6L9′S, but not WT, mice (Figure 6A). The
increases were blocked by mecamylamine pre-injections. Neither
TC299423 nor nicotine affected WT ambulation, and there were
no significant differences between the ambulatory activity of
WT and α6L9′S mice pre-injected mecamylamine. Interestingly,
even the saline-injected α6L9′S mice showed significantly more
ambulation than the WT (p < 0.01). This difference was also
blocked by mecamylamine pre-injection (Figure 6A), suggesting
that it is mediated by the endogenous activation of α6L9′S∗
nAChRs. Thus, consistent with the CPP results above and
previous data (Drenan et al., 2008), the locomotor response of
the mutant α6L9′S mice was more sensitive to nicotine and
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TC299423 than that of the WT mice. The locomotor data also
confirm the activation of α6L9′S∗ nAChRs by a low dose of
TC299423 (0.09 mg/kg in this case).
TC299423 Effect on Antinociception
Previous data show that nicotine is antinociceptive and this effect
is mediated by α4β2∗ (Damaj et al., 2007) and α6∗ nAChRs
(Wieskopf et al., 2015). Because TC299423 is an agonist for α4β2∗
nAChRs at higher doses, we tested its antinociceptive properties
at a dose of 0.3 mg/kg in WT mice using a hot plate assay, and
compared its antinociceptive properties to those of 0.3 mg/kg
nicotine and 0.3 mg/kg varenicline (Figure 6B). The drug
treatments significantly affected responses of WT mice measured
with the hot plate test [One-way ANOVA, F(3,27) = 6.826,
p = 0.0014]. The antinociception elicited by TC299423 was
similar to that elicited by 0.3 mg/kg nicotine. The antinociceptive
effects of both nicotine and TC299423 were significantly greater
than that of varenicline (Figure 6B, p< 0.05).
TC299423 Effect on Anxiety-Related
Behavior
The anxiolytic effects of nicotine may contribute to its rewarding
effects, and appear to be mediated by α4β2∗ nAChRs (Turner
et al., 2010; Anderson and Brunzell, 2012). Marble burying
behavior is a widely used (Deacon, 2006; Yohn and Blendy,
2017) measure of anxiety-related and compulsive behavior in
mice, though interpretation may be complex (Thomas et al.,
2009; Wolmarans de et al., 2016). To compare the anxiolytic
properties of TC299423, varenicline, and nicotine, WT mice
were administered saline, nicotine (0.3 mg/kg), varenicline
(0.3 mg/kg), or TC299423 (0.3 mg/kg) and evaluated with
the marble burying test (Figure 6C). Overall, the drugs
significantly affected the number of marbles buried [One-
way ANOVA, F(3,33) = 45.65, p < 0.001]. Mice buried
significantly fewer marbles following nicotine, TC299423, or
varenicline administration than following saline administration.
Further, mice buried fewer marbles after nicotine or TC299423
injections than varenicline injections (p < 0.001, Figure 6C).
Note that neither nicotine, nor TC299423, significantly reduced
locomotion in WT mice (Figure 6A), rendering it unlikely that
the decrease in marble burying is caused by physical sedation.
DISCUSSION
Our results show that TC299423 is a potent and selective agonist
for α6β2∗ and α4β2∗ nAChRs, compared to α3β4∗ nAChRs
(Figure 3 and Tables 1, 2). In addition, radioligand displacement
assays indicate that TC299423 exhibits virtually no off target
interactions (see Supplementary Table S3). TC299423 is orally
available and crosses the blood-brain barrier (Figure 2 and
Supplementary Table S1). TC299423 has a longer half-life than
nicotine (Petersen et al., 1984) and remains in the brain for at least
60 min following ip injection or oral administration. Experiments
with synaptosomes show that TC299423 elicits α6∗ nAChR-
mediated, striatal [3H]dopamine release. Consistent with these
data, behavioral assays such as CPP (Figure 4) and locomotion
in a novel environment (Figure 6A), which depend on dopamine
release, suggest that TC299423 can elicit dopamine release in vivo.
TC299423 is roughly as effective as nicotine in eliciting locomotor
responses in α6L9′S mice (Figure 6A). Thus, TC299423 is a novel
nAChR agonist that may be useful in studying of nAChR function
and physiology in both in vitro and in vivo systems.
Our in vitro and in vivo data characterizing the properties of
TC299423, along with those reported on the tropane compound,
(+)-pyrido[3,4]homotropane [(+)-PHT] (Carroll et al., 2015)
(see Figure 1 for structure), are promising indications that
selective α6β2∗ nAChR agonists can be identified. Given the
pharmacological similarities between α6∗ and α4∗ nAChRs
(Breining et al., 2009), it has been challenging to identify agonists
that show even modest selectivity. Previous studies indicate that
nicotine is more potent on α4(non-α6)β2∗-nAChRs than it is
on α6(non-α4)β2∗ nAChRs, though it is even more potent on
α4α6β2∗ nAChRs (Salminen et al., 2007; Walsh et al., 2008; Grady
et al., 2010). TC299423, in contrast, appears to be more potent at
α6(non-α4)β2∗ than at α4(non-α6)β2∗-nAChRs (see Table 1 and
Figure 3). Also, it is encouraging that the fold difference between
the EC50 values for α6β2∗ vs. α4β2∗ nAChRs is consistent using
two distinct assays for receptor function: patch-clamp assays on
identified subtypes expressed in cultured cells and [3H]dopamine
release assays using mouse synaptosomes (see Table 1 and
Figure 3). A similar pattern was observed for (+)-PHT (Carroll
et al., 2015), but TC299423 is considerably more potent than (+)-
PHT. An analog of TC299423, 2-(pyridine-3-yl)quinuclidine [see
Figure 1 and (Grady et al., 2010)], also exhibited a similar pattern
in potency among α6β2∗ and α4β2∗ nAChRs. However, PHT was
also relatively potent on α3β4 and α7 nAChRs (EC50 values of
0.43 and 0.66 µM, respectively). Thus, TC299423 is a notable
advance compared to our previous series of small molecules
(Breining et al., 2009; Grady et al., 2010). Although TC299423
shows a preference for α6∗ nAChRs, the difference in potency
between α6∗ and α4∗ nAChRs is not sufficient to label it as an α6∗
selective drug. Thus, the identification of a truly selective small
molecule for α6∗ nAChRs is still to come.
Our pharmacokinetic assays confirm that oral and ip
administrations of TC299423 achieve brain concentrations that
are sufficient for activating nAChRs. Hence, we investigated the
rewarding properties of TC299423 using CPP and nicotine IVSA
assays. Pharmacological and gene deletion studies show that the
β2, α4, and α6 nAChR subunits are critical for nicotine-induced
CPP (Walters et al., 2006; Sanjakdar et al., 2014). Transgenic
mice expressing hypersensitive α6∗ nAChRs exhibit significant
CPP in response to a range of TC299423 doses (see Figure 4).
TC299423 doses in this range do not have a significant overall
effect on CPP in WT mice. However, significant differences
between the CPP of WT and nAChR KO mice (α6KO and
β2KO) in response to a single TC299423 dose (0.012 µg/kg)
suggest that: (1) it has a weakly rewarding effect at this dose
in WT mice, and (2) α6 and β2 nAChR subunits (but not
α4) mediate this effect (see Figure 4A). We did not observe
any difference between TC299423-induced CPP in the WT and
α4KO mice. Thus, the rewarding effects of TC299423 at this
dose are likely to be mediated by α6(non-α4)β2∗ nAChRs, rather
than α4α6β2∗ or α4β2 nAChRs. Our KO data also suggest that
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FIGURE 6 | Locomotor, anxiolytic and analgesic effects of TC299423. (A) Locomotor activity of WT and α6L9′S mice in a novel environment. Mice were injected ip
with saline, 0.08 mg/kg nicotine, or 0.09 mg/kg TC299423, and their locomotor activity was measured. Mice were also pre-injected with saline or 1 mg/kg
mecamylamine prior to testing (n = 8–32). Pre-injection with mecamylamine blocked nicotine- and TC29942-mediated increase in locomotor activity in the α6L9’S
mice. (B) The effects of nicotine, varenicline, and TC299423 (0.3 mg/kg for each) on antinociception were measured using the hot-plate test (n = 7–8 mice). (C) The
effects of nicotine, varenicline, and TC299423 (0.3 mg/kg for each) on marble burying were measured (n = 8–11 mice). In all panels, data presented are
mean ± SEM: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 [Two-way ANOVA with post hoc Tukey (A) or One-way ANOVA with post hoc Tukey (B,C)].
TC299423 reward-related behavior in WT and α6L9′S mice is
mediated via nAChRs, rather than via off-target responses. The
contribution of the α6∗ nAChRs to TC299423-induced CPP is
reinforced by its potency in establishing CPP in the α6L9′S mice
(see Figure 4C). The enhanced sensitivity of α6L9′S mice to
TC299423-induced CPP is consistent with previous cellular and
behavioral data showing an enhanced sensitivity to nicotine as
well (Drenan et al., 2008; Drenan and Lester, 2012). Interestingly,
the effects of TC299423 on CPP in α6KO and α4KO differ from
that of nicotine (Sanjakdar et al., 2014). (+)-PHT also elicits
CPP in mice, but at higher doses than TC299423 (Carroll et al.,
2015).
We did not find any effects of low-dose TC299423 on nicotine
IVSA or food reward in rats. Nicotine has reinforcing behavioral
effects through activation and desensitization of nAChRs in
the central nervous system. β2∗ nAChRs, which often contain
α4 and/or α6 subunits, are necessary for nicotine IVSA and
CPP (Picciotto et al., 1998; Maskos et al., 2005; Walters et al.,
2006). α4∗ nAChRs are sufficient for establishing nicotine CPP
(Tapper et al., 2004; McGranahan et al., 2011), but apparently
not necessary (Cahir et al., 2011). They are also important, if
not necessary, for nicotine IVSA (Cahir et al., 2011). Similarly,
α6∗ nAChRs are sufficient for nicotine CPP (Drenan et al.,
2012), but not necessary (Sanjakdar et al., 2014), and appear
to be necessary for nicotine IVSA (Pons et al., 2008). Recent
investigations using smoking-relevant concentrations of nicotine
highlight the importance of activating VTA nAChRs that contain
both the α4 and α6 nAChR subunits (Liu et al., 2012; Engle et al.,
2013) and suggest that α4α6β2∗ nAChRs are a primary target
for nicotine. In the context of nicotine IVSA, α4∗, α6∗, and β2∗
nAChRs are certainly involved, but one must also consider the
involvement of α4α6β2∗ nAChRs.
While TC299423 had no effect on nicotine IVSA, several
nAChR ligands have been shown to reduce nicotine IVSA:
varenicline (Rollema et al., 2007), sazetidine-A (Pałczyñska
et al., 2012), mecamylamine (DeNoble and Mele, 2006; Fowler
and Kenny, 2014), bupropion (Bruijnzeel and Markou, 2003),
and cytisine (Radchenko et al., 2015). Multiple mechanisms
can account for the failure of a low-dose of TC299423 to
suppress nicotine IVSA. First, the suppressive effects of nicotine,
varenicline, and sazetidine-A may arise from their effects on
α4β2∗, rather than α6β2, nAChRs. Second, the rewarding effects
of TC299423 at the dosages used may be insufficient to substitute
for those of nicotine. Third, we note a key difference between
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TC299423 and drugs that have been shown to alter nicotine
reinforcement: varenicline, cytisine, and bupropion are all partial
agonists shown to decrease nicotine IVSA or nicotine CPP
(Bruijnzeel and Markou, 2003; Rollema et al., 2010) but they
also act as nAChR antagonists (Slemmer et al., 2000; Mihalak
et al., 2006; Papke et al., 2011). Additionally, previous studies
show that potent nAChR antagonists decrease nicotine CPP and
nicotine IVSA (DeNoble and Mele, 2006; Sanjakdar et al., 2014).
We did not observe that TC299423 acts as an antagonist on
nAChRs and this could be a key mechanistic reason why it
does not alter nicotine reinforcement. Finally, TC299423 may
enhance both the reinforcing and aversive properties of nicotine,
effectively neutralizing the effects on nicotine IVSA. There is
a dense population of α6∗ nAChRs in the medial habenula
(Henderson et al., 2014; Shih et al., 2014) and this region regulates
nicotine aversion (Fowler et al., 2011). However, all reports of
this phenomena point to α2∗, α5∗, and β4∗ nAChRs mediating
aversion to nicotine (Salas et al., 2009; Fowler et al., 2011); and
direct involvement of α6 nAChR subunits has yet to be examined.
If α6∗ nAChRs also mediate aversive responses in the medial
habenula, TC299423 stimulation of α6∗ nAChRs may produce
a simultaneous enhancement of rewarding and aversive stimuli.
While it is currently unknown whether α6∗ nAChRs play a role
in nicotine aversion, we note that α6∗ nAChRs play a critical role
in affective nicotine withdrawal behavior (Jackson et al., 2009).
Nicotine’s anxiolytic and analgesic properties are also
considered contributing factors to nicotine addiction. We
measured anxiety-related behavior and nociception in mice using
the marble burying and hot-plate assays, respectively. Nicotine’s
anxiolytic and nociceptive properties are believed to be primarily
mediated by α4β2∗ nAChRs (Bannon et al., 1998; Vincler and
Eisenach, 2005; Turner et al., 2010; Zhang et al., 2012; Hone et al.,
2013). Thus, we used a higher dose of TC299423 for these assays
(0.3 mg/kg) than in the CPP assays, to ensure activation of α4β2∗
receptors. We found that TC299423 resembles nicotine in both
its anxiolytic and antinociceptive properties, and is more potent
and/or efficacious in each than varenicline (see Figure 6).
Overall, our results represent a thorough pharmacological
investigation (in vivo and in vitro) of the novel nAChR agonist,
TC299423. Our data suggest that TC299423 is a full agonist at
α4β2∗ nAChRs and support a previous conclusion that TC299423
is a partial agonist at α6β2∗ nAChRs (Post et al., 2015). Similar
to CNS penetrant nAChR partial agonists (e.g., varenicline),
TC299423 potently activates β2∗ nAChRs and exhibits suitable
pharmacokinetic characteristics for use in vivo. TC299423
potently elicits reward-related behavior in hypersensitive α6L9′S
mice and perhaps WT mice. At low doses, TC299423-initiated
reward is primarily mediated through α6∗ nAChRs, not α4∗
nAChRs. Our studies of TC299423 and nicotine IVSA show that
TC299423 at the low doses we tested is not efficacious in altering
nicotine reinforcement. Nevertheless, TC299423 is a potent and
novel nAChR agonist that could be useful for the future study of
nAChR-related function and physiology.
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